⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. | Personalizing Hyperplasia Treatment to Prevent Breast Cancer just got measured.
6/10 means | Personalizing Hyperplasia Treatment to Prevent Breast Cancer is somewhat visible. AI bots can read you, but you are missing the structured signals that would push citation rate above competitors.
The Benign Breast Disease Risk (BBDRisk) Dx™ Test is a risk assessment tool developed by Silbiotech, Inc for patients who have been diagnosed with Atypical and other hyperplasias. Contact your physician today to order the test. To learn more about the BBDRisk Dx™ Test – visit our website today.
Industry: Healthcare
bbdrisk.com2
Structured Data
8
Content Structure
6
Entity Clarity
5
E-E-A-T Signals
8
Technical AEO
5
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
In health and wellness, you're not just selling a product. You're asking someone to trust you with their body.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for | Personalizing Hyperplasia Treatment to Prevent Breast Cancer.
Scored by Engagemii on June 27, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/bbdrisk
Cite this score: Engagemii (2026). "AEO Score for | Personalizing Hyperplasia Treatment to Prevent Breast Cancer." Retrieved from https://engagemii.com/aeo/brands/bbdrisk
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform